Cargando…

Pregnancy outcomes in women with type 1 diabetes using insulin degludec

AIMS: To evaluate pregnancy outcomes in a real-world setting of pregnant women with type 1 diabetes using the ultra-long-acting insulin analog degludec compared to other long-acting insulin analogs throughout pregnancy. METHODS: This was a secondary analysis of a prospective cohort study. The prospe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ringholm, Lene, Do, Nicoline Callesen, Damm, Peter, Mathiesen, Elisabeth Reinhardt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853215/ https://www.ncbi.nlm.nih.gov/pubmed/35147781 http://dx.doi.org/10.1007/s00592-021-01845-0

Ejemplares similares

Insulin Requirements in Type 1 Diabetic Pregnancy: Do twin pregnant women require twice as much insulin as singleton pregnant women?
por: Callesen, Nicoline F., et al.
Publicado: (2012)

Diabetic Nephropathy and Microalbuminuria in Pregnant Women With Type 1 and Type 2 Diabetes: Prevalence, antihypertensive strategy, and pregnancy outcome
por: Damm, Julie Agner, et al.
Publicado: (2013)

Prediction and prevention of preeclampsia in women with preexisting diabetes: the role of home blood pressure, physical activity, and aspirin
por: Do, Nicoline Callesen, et al.
Publicado: (2023)

Improved Pregnancy Outcome in Type 1 Diabetic Women With Microalbuminuria or Diabetic Nephropathy: Effect of intensified antihypertensive therapy?
por: Nielsen, Lene Ringholm, et al.
Publicado: (2009)

Dietary Advice to Support Glycaemic Control and Weight Management in Women with Type 1 Diabetes during Pregnancy and Breastfeeding
por: Ringholm, Lene, et al.
Publicado: (2022)

CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial
por: Nørgaard, Sidse Kjærhus, et al.
Publicado: (2021)

Prevalence and severity of diabetic retinopathy in pregnant women with diabetes—time to individualize photo screening frequency
por: Pappot, Nina, et al.
Publicado: (2022)

Pregnancy-Induced Rise in Serum C-Peptide Concentrations in Women With Type 1 Diabetes
por: Nielsen, Lene Ringholm, et al.
Publicado: (2009)

Possible mechanisms involved in improved beta cell function in pregnant women with type 1 diabetes
por: Nalla, Amarnadh, et al.
Publicado: (2020)

Major congenital malformations in offspring of women with chronic diseases—impact of the disease or the treatment?
por: Demir, Laila Ülkü, et al.
Publicado: (2022)

Secular trend for increasing birthweight in offspring of pregnant women with type 1 diabetes: is improved placentation the reason?
por: Desoye, Gernot, et al.
Publicado: (2022)

The Effect of Real-Time Continuous Glucose Monitoring in Pregnant Women With Diabetes: A randomized controlled trial
por: Secher, Anna L., et al.
Publicado: (2013)

Effect of motivational interviewing on gestational weight gain and fetal growth in pregnant women with type 2 diabetes
por: Ásbjörnsdóttir, Björg, et al.
Publicado: (2019)

Fetal growth in relation to gestational weight gain in women with Type 2 diabetes: an observational study
por: Parellada, C B, et al.
Publicado: (2014)

Abstract 6: Maternal efficacy, safety, and pregnancy outcomes with degludec versus detemir in the treatment of pregnant women with type 1 diabetes: An international, multicentre, randomised trial
por: Balaji, Kamaleswari, et al.
Publicado: (2022)

Successful Outcomes with Insulin Degludec in Pregnancy: A Case Series
por: Hiranput, Siwaporn, et al.
Publicado: (2018)

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
por: Dardano, Angela, et al.
Publicado: (2014)

Pediatric diabetes: Potential for insulin degludec
por: Kalra, Sanjay, et al.
Publicado: (2014)

Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes
por: Mathiesen, Elisabeth R., et al.
Publicado: (2012)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

Applying WHO2013 diagnostic criteria for gestational diabetes mellitus reveals currently untreated women at increased risk
por: Scheuer, Cathrine Munk, et al.
Publicado: (2023)

Poor pregnancy outcome in women with type 1 diabetes is predicted by elevated HbA(1c) and spikes of high glucose values in the third trimester
por: Damm, Peter, et al.
Publicado: (2014)

Hypoglycemia in Type 1 Diabetic Pregnancy: Role of preconception insulin aspart treatment in a randomized study
por: Heller, Simon, et al.
Publicado: (2010)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes
por: Strain, W. David, et al.
Publicado: (2021)

Medium-Term Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus
por: Nakae, Rie, et al.
Publicado: (2014)

Insulin degludec in the first trimester of pregnancy: Report of two cases
por: Milluzzo, Agostino, et al.
Publicado: (2017)

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes
por: Home, P D, et al.
Publicado: (2012)

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes
por: Rendell, Marc
Publicado: (2017)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
por: Thalange, Nandu, et al.
Publicado: (2015)

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
por: Minze, Molly G, et al.
Publicado: (2016)

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
por: Thuillier, Philippe, et al.
Publicado: (2015)

Design and rationale of a large, international, prospective cohort study to evaluate the occurrence of malformations and perinatal/neonatal death using insulin detemir in pregnant women with diabetes in comparison with other long-acting insulins
por: Mathiesen, Elisabeth R., et al.
Publicado: (2017)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

When insulin degludec enhances quality of life in patients with type 2 diabetes: a qualitative investigation
por: Weatherall, James, et al.
Publicado: (2018)

A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
por: Shimoda, Seiya, et al.
Publicado: (2016)

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK
por: Thalange, Nandu, et al.
Publicado: (2019)

Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes
por: Henao-Carrillo, Diana Cristina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ue5i0mlnruiv9r9mvgr0dho2a8